<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242020000502424</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Los ensayos clínicos en la ruta del cáncer a la cronicidad]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical trials in the way of cancer to a chronic disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Suárez]]></surname>
<given-names><![CDATA[Anairis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Hernández]]></surname>
<given-names><![CDATA[Mildrey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Comandante Faustino Pérez Hernández  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<volume>42</volume>
<numero>5</numero>
<fpage>2424</fpage>
<lpage>2429</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242020000502424&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242020000502424&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242020000502424&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El cáncer es actualmente uno de los problemas de salud más importantes en la mayoría de los países occidentales. En Cuba, el cáncer es la segunda causa de muerte para todos los grupos de edad superada solo por las enfermedades cardiovasculares. En Matanzas, en los últimos años el cáncer ha mostrado una tendencia creciente con datos de incidencia y prevalencia por encima de la media del país. Por tales motivos realizamos este estudio con el objetivo de evaluar el impacto de la inmunoterapia como una alternativa terapéutica que mejora las funciones de supervivencia en pacientes con cáncer avanzado.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Cancer is actually one of the most important health problems in the occidental countries. In Cuba, cancer is the second cause of death in all ages, under heart diseases. In Matanzas, in the last years cancer had showed and ascending growth on incidence and prevalence, over country media. That is wy, we make this study with the objective to evaluate the impact of inmunotherapy as a therapeutic alternative which increase the survival function in patients with advanced cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="es"><![CDATA[ensayos clínicos]]></kwd>
<kwd lng="es"><![CDATA[enfermedad crónica]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[clinical trials]]></kwd>
<kwd lng="en"><![CDATA[chronic disease]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnedillo Muñoz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Merino Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del Cáncer de pulmón en el ámbito de Neumosur]]></article-title>
<source><![CDATA[Rev Española de patología torácica]]></source>
<year>2017</year>
<numero>^smarzo</numero>
<issue>^smarzo</issue>
<supplement>marzo</supplement>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gospodarowicz]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Cazap]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jadad]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer in the world: a call for international collaboration]]></article-title>
<source><![CDATA[Salud Pública Méx]]></source>
<year>2009</year>
<volume>51</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>s305-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saurez Martínez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bencomo Yanes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nimotuzumab, effective immunotherapy for the treatment of malignant epithelial tumor]]></article-title>
<source><![CDATA[Biotecnol Apl]]></source>
<year>2014</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<numero>^s8</numero>
<issue>^s8</issue>
<supplement>8</supplement>
<page-range>28-34</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Chiappori]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer]]></article-title>
<source><![CDATA[Cancer Cont]]></source>
<year>2013</year>
<volume>20</volume>
<page-range>22-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callahan]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Wolchok]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy]]></article-title>
<source><![CDATA[Semin Oncol]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>437-84</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramalingam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)]]></article-title>
<source><![CDATA[Annals Oncol]]></source>
<year>2013</year>
<volume>24</volume>
<page-range>2875-80</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year>2017</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1568-80</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casciato]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Oncología Clínica]]></source>
<year>2017</year>
<edition>8va</edition>
<publisher-loc><![CDATA[Filadelfia ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Klubber]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>MINSAP</collab>
<source><![CDATA[Anuario Estadístico de Salud]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Cuba ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escarlata López]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[El paciente oncológico. Atención compartida]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Granada ]]></publisher-loc>
<publisher-name><![CDATA[Hospital La Inmaculada]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bender]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer immunotherapy]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2017</year>
<volume>552</volume>
<numero>7685</numero>
<issue>7685</issue>
<page-range>S61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Restifo]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Dudley]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adoptive immunotherapy for cancer: harnessing the T cell esponse]]></article-title>
<source><![CDATA[Nat Rev Immunology]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>269-81</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
